61.23
price down icon1.76%   -1.10
 
loading
前日終値:
$62.33
開ける:
$62.01
24時間の取引高:
985.43K
Relative Volume:
0.65
時価総額:
$8.51B
収益:
$105.82M
当期純損益:
$-829.61M
株価収益率:
-8.948
EPS:
-6.8429
ネットキャッシュフロー:
$-548.92M
1週間 パフォーマンス:
-1.16%
1か月 パフォーマンス:
-6.96%
6か月 パフォーマンス:
-6.49%
1年 パフォーマンス:
+6.49%
1日の値動き範囲:
Value
$60.89
$62.44
1週間の範囲:
Value
$60.89
$64.78
52週間の値動き範囲:
Value
$54.30
$88.31

Cytokinetics Inc Stock (CYTK) Company Profile

Name
名前
Cytokinetics Inc
Name
セクター
Healthcare (1052)
Name
電話
(650) 624-3000
Name
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
職員
673
Name
Twitter
@Cytokinetics
Name
次回の収益日
2026-11-04
Name
最新のSEC提出書
Name
CYTK's Discussions on Twitter

Compare CYTK vs VRTX, REGN, MRNA, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CYTK icon
CYTK
Cytokinetics Inc
61.23 8.51B 105.82M -829.61M -548.92M -6.8429
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
523.93 132.80B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
805.02 82.88B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
200.10 79.89B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
873.71 54.94B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
377.63 42.72B 5.76B 514.49M 1.10B 4.4813

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-06-29 アップグレード UBS Neutral → Buy
2026-05-19 開始されました Citigroup Buy
2026-04-10 開始されました Wells Fargo Overweight
2026-01-28 再開されました Barclays Overweight
2025-12-18 アップグレード Goldman Neutral → Buy
2025-07-30 再開されました Raymond James Mkt Perform
2025-04-24 開始されました Barclays Overweight
2025-02-07 開始されました Citigroup Buy
2025-01-22 開始されました Stifel Buy
2024-11-08 開始されました RBC Capital Mkts Outperform
2024-08-13 ダウングレード Goldman Buy → Neutral
2024-01-24 ダウングレード UBS Buy → Neutral
2024-01-05 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-11-09 開始されました Goldman Buy
2023-11-07 開始されました B. Riley Securities Buy
2023-08-15 開始されました SVB Securities Outperform
2023-02-17 開始されました BofA Securities Neutral
2022-12-23 繰り返されました Needham Buy
2022-12-20 開始されました Truist Buy
2022-10-11 開始されました UBS Buy
2022-01-28 開始されました Goldman Buy
2021-12-22 開始されました Oppenheimer Outperform
2021-12-10 開始されました JP Morgan Overweight
2021-10-07 開始されました Jefferies Buy
2021-03-12 開始されました Wolfe Research Outperform
2021-02-18 開始されました Barclays Overweight
2021-01-20 繰り返されました H.C. Wainwright Buy
2020-10-29 開始されました Goldman Neutral
2020-07-10 開始されました Raymond James Strong Buy
2020-05-05 開始されました Mizuho Buy
2020-04-09 アップグレード Morgan Stanley Equal-Weight → Overweight
2018-09-21 開始されました Cantor Fitzgerald Overweight
2018-09-10 再開されました Morgan Stanley Equal-Weight
2017-11-22 繰り返されました Morgan Stanley Overweight
2017-11-22 ダウングレード Needham Strong Buy → Buy
2017-11-21 繰り返されました H.C. Wainwright Buy
2017-07-31 開始されました Morgan Stanley Overweight
2017-03-08 開始されました Rodman & Renshaw Buy
2017-02-06 アップグレード Needham Buy → Strong Buy
2016-12-16 開始されました Cantor Fitzgerald Overweight
2016-07-28 繰り返されました Needham Buy
2015-11-10 繰り返されました FBR Capital Outperform
2015-11-09 繰り返されました ROTH Capital Buy
2015-07-24 繰り返されました MLV & Co Buy
2014-12-31 繰り返されました ROTH Capital Buy
2014-11-04 アップグレード MLV & Co Hold → Buy
2014-04-28 繰り返されました Needham Buy
すべてを表示

Cytokinetics Inc (CYTK) 最新ニュース

pulisher
Oct 21, 2026

Cytokinetics to Announce Third Quarter Results on November 4, 2026 - GlobeNewswire Inc.

Oct 21, 2026
pulisher
Oct 20, 2026

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Oct 20, 2026
pulisher
Oct 20, 2026

Form 4 Cytokinetics Inc: Nancy Wysenski (Director) For: 16 October By Investing.com - Investing.com Canada

Oct 20, 2026
pulisher
Oct 20, 2026

195 shares replace a cash retainer for Cytokinetics (CYTK) director Edward M. Kaye. - Stock Titan

Oct 20, 2026
pulisher
Oct 20, 2026

A 195-share award brings Harrington's direct Cytokinetics (CYTK) holdings to 22,127 shares. - Stock Titan

Oct 20, 2026
pulisher
Oct 20, 2026

Cytokinetics Director Wendell Wierenga Purchases 97 Shares at $63.92 Each - Kalkine Media

Oct 20, 2026
pulisher
Oct 20, 2026

Shares replace a cash retainer as Cytokinetics (CYTK) director Henderson receives 352 shares. - Stock Titan

Oct 20, 2026
pulisher
Oct 20, 2026

Officer Fady Malik proposes selling 16,386 Cytokinetics (CYTK) shares from option exercises. - Stock Titan

Oct 20, 2026
pulisher
Oct 20, 2026

RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $113 - Moomoo

Oct 20, 2026
pulisher
Oct 19, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Oct 19, 2026
pulisher
Oct 19, 2026

29 new hires at Cytokinetics received stock awards. Share awards vest over 3 years; options over 4. - Stock Titan

Oct 19, 2026
pulisher
Oct 19, 2026

BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - www.marketscreener.com

Oct 19, 2026
pulisher
Oct 19, 2026

BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - Yahoo Finance

Oct 19, 2026
pulisher
Oct 19, 2026

CYTK Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus

Oct 19, 2026
pulisher
Oct 19, 2026

HC Wainwright & Co. reiterates Buy rating on Cytokinetics, $140 price target - TradingView

Oct 19, 2026
pulisher
Oct 19, 2026

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth? - Yahoo Finance

Oct 19, 2026
pulisher
Oct 19, 2026

BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains Neutral Rating - Yahoo Finance

Oct 19, 2026
pulisher
Oct 19, 2026

Canada authorizes a drug for adults whose thickened heart muscle blocks blood flow - Stock Titan

Oct 19, 2026
pulisher
Oct 19, 2026

Cytokinetics Announces Health Canada Approval of MYQORZO® - GlobeNewswire

Oct 19, 2026
pulisher
Oct 16, 2026

CYTK Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus

Oct 16, 2026
pulisher
Oct 16, 2026

William Blair Initiates Coverage on Cytokinetics With Outperform Rating - Yahoo Finance

Oct 16, 2026
pulisher
Oct 15, 2026

William Blair initiates Cytokinetics stock coverage with outperform rating By Investing.com - Investing.com South Africa

Oct 15, 2026
pulisher
Oct 15, 2026

William Blair initiates Cytokinetics stock coverage with outperform rating - Investing.com

Oct 15, 2026
pulisher
Oct 15, 2026

Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today - Benzinga

Oct 15, 2026
pulisher
Oct 15, 2026

Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK

Oct 15, 2026
pulisher
Oct 15, 2026

Cytokinetics Sees Myqorzo Launch Strength Carry Into 2027, RBC Says - marketscreener.com

Oct 15, 2026
pulisher
Oct 15, 2026

Cytokinetics (NasdaqGS:CYTK) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 15, 2026
pulisher
Oct 14, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance

Oct 14, 2026
pulisher
Oct 14, 2026

UBS cuts Cytokinetics stock price target on valuation, keeps Buy - Investing.com

Oct 14, 2026
pulisher
Oct 13, 2026

Cytokinetics Insider Sold Shares Worth $471,600, According to a Recent SEC Filing - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. - Stock Titan

Oct 13, 2026
pulisher
Oct 13, 2026

Cytokinetics (CYTK), What Is Behind The Fresh Attention? - Yahoo Finance

Oct 13, 2026
pulisher
Oct 12, 2026

Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Cytokinetics presents additional aficamten data from trial - Investing.com

Oct 12, 2026
pulisher
Oct 12, 2026

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo. - Stock Titan

Oct 12, 2026
pulisher
Oct 12, 2026

Cytokinetics Q2 2026 Earnings Call: Complete Transcript - Benzinga

Oct 12, 2026
pulisher
Oct 11, 2026

Cytokinetics EVP Fady Malik sells $214,830 in company stock - Investing.com

Oct 11, 2026
pulisher
Oct 11, 2026

Form 4 Cytokinetics Inc For: 11 October By Investing.com - Investing.com Nigeria

Oct 11, 2026
pulisher
Oct 08, 2026

CYTK6536068 Bond Yield and Price — FINRA:CYTK6536068 - TradingView

Oct 08, 2026
pulisher
Oct 07, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance

Oct 07, 2026
pulisher
Oct 06, 2026

Cytokinetics Inc (CYTK) EVP Research & Development Fady Malik Se - GuruFocus

Oct 06, 2026
pulisher
Oct 06, 2026

Cytokinetics (CYTK): Company Profile, Stock Price, News, Rankings - Fortune

Oct 06, 2026
pulisher
Oct 05, 2026

Cytokinetics Falls as Investors Appear to Take Profits Despite Recent Aficamten Progress - Quiver Quantitative

Oct 05, 2026
pulisher
Oct 04, 2026

CYTK6536068 Bond Profile: Coupon and Redemption - TradingView

Oct 04, 2026
pulisher
Oct 03, 2026

Wells Fargo Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $105 - Moomoo

Oct 03, 2026
pulisher
Oct 03, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada

Oct 03, 2026
pulisher
Oct 02, 2026

Cytokinetics Inc. Advanced Charts | CYTK - Barron's

Oct 02, 2026
pulisher
Oct 02, 2026

Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy - Quiver Quantitative

Oct 02, 2026

Cytokinetics Inc (CYTK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Cytokinetics Inc (CYTK) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Malik Fady Ibraham
EVP Research & Development
Oct 20 '26
Option Exercise
7.80
3,500
27,300
157,402
Malik Fady Ibraham
EVP Research & Development
Oct 20 '26
Sale
64.01
3,500
224,035
153,902
Blum Robert I
President & CEO
Oct 12 '26
Option Exercise
10.60
7,500
79,500
286,044
Blum Robert I
President & CEO
Oct 12 '26
Sale
62.88
7,500
471,600
278,544
ROBERT BLUM
Director
Oct 12 '26
Proposed Sale
62.91
22,500
1,415,475
0
Malik Fady Ibraham
EVP Research & Development
Oct 06 '26
Option Exercise
7.80
3,500
27,300
157,402
Malik Fady Ibraham
EVP Research & Development
Oct 06 '26
Sale
61.38
3,500
214,830
153,902
Blum Robert I
President & CEO
Sep 28 '26
Sale
65.46
7,500
490,950
278,544
Blum Robert I
President & CEO
Sep 28 '26
Option Exercise
10.60
7,500
79,500
286,044
Malik Fady Ibraham
EVP Research & Development
Sep 22 '26
Option Exercise
7.80
3,500
27,300
157,402
$90.33
price down icon 2.17%
$8.22
price down icon 1.08%
$54.17
price up icon 1.90%
$58.02
price down icon 0.58%
$138.43
price down icon 0.79%
CAI CAI
$32.00
price up icon 0.91%
大文字化:     |  ボリューム (24 時間):